Reviewing Integra LifeSciences (NASDAQ:IART) & Carmell (NASDAQ:CTCX)

Integra LifeSciences (NASDAQ:IART) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk & Volatility

Integra LifeSciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Integra LifeSciences and Carmell, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	4	3	2	0	1.78
Carmell	0	0	0	0	N/A

Integra LifeSciences currently has a consensus price target of $28.63, suggesting a potential upside of 49.17%. Given Integra LifeSciences’ higher possible upside, equities analysts plainly believe Integra LifeSciences is more favorable than Carmell.

Profitability

This table compares Integra LifeSciences and Carmell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	1.51%	14.07%	5.66%
Carmell	N/A	-148.47%	-40.47%

Insider and Institutional Ownership

84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 24.2% of Carmell shares are held by institutional investors. 3.1% of Integra LifeSciences shares are held by company insiders. Comparatively, 29.0% of Carmell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Integra LifeSciences and Carmell’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.57 billion	0.97	$67.74 million	$0.50	38.38
Carmell	$12,320.00	837.35	-$15.44 million	N/A	N/A

Integra LifeSciences has higher revenue and earnings than Carmell.

Summary

Integra LifeSciences beats Carmell on 9 of the 11 factors compared between the two stocks.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.